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After the introduction of solvent/detergent-treated
plasma (ESDEP®) in our hospital, an increased inci-
dence of hyperfibrinolysis was observed (75% vs 29%; P
 0.005) compared with the use of fresh frozen plasma
for liver transplantation. To clarify this increased inci-
dence, intraoperative plasma samples of patients
treated with fresh frozen plasma or ESDEP were ana-
lyzed in a retrospective observational study. During the
anhepatic phase, plasma levels of d-dimer (6.58 vs 1.53
g/mL; P 0.02) and fibrinogen degradation products
(60 vs 23 mg/L; P 0.018) were significantly higher in
patients treated with ESDEP. After reperfusion, differ-
ences increased to 23.5 vs 4.7 g/mL (d-dimer, P 
0.002) and 161 vs 57 mg/L (fibrinogen degradation
products, P  0.001). The amount of plasma received
per packed red blood cell concentrate, clotting tests,
and levels of individual clotting factors did not show
significant differences between the groups. 2-
Antiplasmin levels, however, were significantly lower
in patients receiving ESDEP during the anhepatic phase
(0.37 vs 0.65 IU/mL; P  0.001) and after reperfusion
(0.27 vs 0.58 IU/mL; P  0.001). Analysis of 2-
antiplasmin levels in ESDEP alone showed a reduction
to 0.28 IU/mL (normal 0.95 IU/mL) because of the
solvent/detergent process. Therapeutic consequences
for the use of ESDEP in orthotopic liver transplantation
are discussed in view of an increased incidence of hy-
perfibrinolysis caused by reduced levels of 2-
antiplasmin in the solvent/detergent-treated plasma.
(Anesth Analg 2002;94:1127–31)
T o minimize the risk of transmission of the lipid-coated viruses hepatitis B virus, hepatitis C virus,and human immunodeficiency virus in blood com-
ponent substitution therapy, solvent/detergent (SD)-
treated plasma has been used in our hospital since 1996.
Since its introduction, an increase in hyperfibrinolysis
during orthotopic liver transplantation (OLT) has been
observed. Enhanced fibrinolytic activity during OLT has
been attributed to high levels of tissue-type plasminogen
activator (t-PA) (1,2) and contributes to serious bleeding
complications (3). Plasma levels of t-PA peak just after
reperfusion as a result of the absent clearance during the
anhepatic phase and the release of t-PA from damaged
endothelial cells in the donor liver (4). In vitro studies
demonstrated some alterations in individual clotting fac-
tors caused by SD treatment, particularly a loss of clot-
ting factor VIII (up to 20%), protein S (35%), and 2-
antiplasmin (up to 76%) (5,6). In this observational study,
intraoperative plasma samples of patients treated with
SD-treated plasma or fresh-frozen plasma (FFP) were
analyzed to find an explanation for the increased inci-
dence of hyperfibrinolysis observed with the use of
SD-treated plasma (ESDEP®; CLB Amsterdam, The
Netherlands) during OLT.
Methods
All the studies, including this study, running in the
Rotterdam liver transplantation center are under the sur-
veillance of the medical ethics committee of the Erasmus
University Rotterdam. From June 1994 to March 1997, 67
patients underwent OLT for end-stage cirrhosis after
written, informed consent was obtained. In 41 patients,
complete coagulation follow-up during the procedure
was present. From June 1994 to December 1995, clotting
factors were substituted in 21 patients with FFP (300 mL;
CLB Amsterdam). After January 1996, SD virus-
inactivated plasma (ESDEP, 200 mL) was used in 20
patients. The ESDEP was prepared from pooled plasma
of 2000 voluntary Dutch blood donors, and virus inacti-
vation was realized by treating the pooled plasma with
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1% tri-(n-butyl)phosphate and 1% Triton X-100 (7) by
Octapharma (Octapharma, Vienna, Austria). Anesthesia
was induced with Thiopental 3–4 mg/kg, midazolam
0.1 mg/kg, and sufentanil 0.5 g/kg. Muscle relaxation
was achieved with pancuronium 0.1 mg/kg. Anesthesia
was maintained with midazolam 0.1 mg · kg1 · h1,
sufentanil 0.2 g · kg1 · h1, and pancuronium 25 g/
kg. Calcium chloride was given by infusion as required.
Inotropic support was provided if necessary with dopa-
mine 5–10 g · kg1 · min1 and, sometimes, epineph-
rine 0.25 g · kg1 · min1. Packed red blood cells
(PRBC) were transfused to maintain a hematocrit of 25%.
FFP or ESDEP was infused 10 mL/kg in the preanhe-
patic phase to correct severe coagulopathy and was then
infused in a ratio of 1 mL/mL PRBC or per milliliter of
salvaged blood. Platelet count was kept80 109/L by
infusion of platelet suspension. If fibrinogen decreased
to 1.0 g/L, purified fibrinogen (Hemocomplettan P;
CLB Amsterdam) was given. A venovenous bypass with
heparin-coated tubing (Bioconsole; Biomedicus, Minne-
apolis, MN) was used after trial clamping of the caval
vein. A blood cell salvage system (CATS; Fresenius,
Schweinfurt, Germany) and rapid infusion system (Hae-
monetics, Braintree, MA) were routinely used.
Routine coagulation tests (activated partial throm-
boplastin time, partial thromboplastin time, thrombo-
cyte count, thrombin time 5E and 10E, fibrinogen,
Thrombotest™, and Normotest™) were performed on
arterial blood collected 5 min after the induction of
anesthesia (but before the administration of plasma),
5 min after hepatectomy, 5 min after reperfusion of the
donor liver, and at the end of the procedure. Fibrino-
lysis was detected with four-channel Thrombelasto-
graph (TEG®; Haeomoscope Corp., Skokie, IL) record-
ings according to the criteria of Kang et al. (8),
standard at sampling times and further when clini-
cally indicated. The following values were measured:
reaction time, coagulation time, maximal amplitude
(MA), and clot lysis index (CLI) at 30 and 60 min (MA
MAt)/MA  100%. Tranexamic acid (500–1000 mg)
was administered when TEG® recordings showed a
CLI60 of more than 10% and generalized oozing oc-
curred. After the administration of tranexamic acid,
the result was evaluated with a new TEG® recording,
and, if necessary, the treatment was repeated with
dosages of 10–15 mg · kg1 · h1. To confirm the di-
agnosis of fibrinolysis, d-dimers were analyzed after-
ward in stored plasma by using the Miniquant auto-
mated agglutination analyzer and Miniquant test kit
(Biopool Kordia, Leiden, The Netherlands). Fibrino-
gen degradation products (FDP) were also analyzed in
stored plasma by using a Latex agglutination reaction
(Diagnostica Stago Roche, The Netherlands). Clotting
factor II, VII, VIII, IX, and X levels were analyzed
afterward by standard clotting assays in stored
plasma (80°C) on an automatic coagulation labora-
tory (Instrumentation Laboratory, Breda, The Nether-
lands) by using human deficient plasma (Biopool Kor-
dia). Antithrombin-III and 2-antiplasmin were
determined with a chromogenic assay (Dade-Behring,
Leusden, The Netherlands). All data are presented as
mean sem. After normality was tested with Shapiro-
Wilk statistics, a Student’s t-test or Mann-Whitney
U-test was used for data analysis. 2-Antiplasmin lev-
els had logarithmic transformation before analysis,
and the changes from baseline 2-antiplasmin levels
were investigated with repeated-measures analysis of
variance including time period and type of plasma as
covariates. For 2  2 table data, the 2 test with the
Yates correction or Fisher’s exact test was used. Dif-
ferences were considered significant for P  0.05.
Results
The characteristics of the FFP- and ESDEP-Treated
groups are summarized in Table 1. In patients treated
with FFP (n  21), hyperfibrinolysis was seen in six
individuals (29%): in one patient during the preanhe-
patic phase, in one patient during both the preanhe-
patic and the anhepatic phase, in one patient during
both the anhepatic and reperfusion phase, and in three
patients after reperfusion. In the ESDEP-Treated
group (n  20), hyperfibrinolysis was present in 15
patients (75% vs 29%; P  0.005). In 4 patients, an
episode of hyperfibrinolysis occurred during the pre-
anhepatic phase (20% vs 10%; not significant); in 8
patients, during the anhepatic phase (40% vs 10%; P
0.03); and in 10 patients, after reperfusion (50% vs
19%; P  0.05). In 7 of these 15 patients with hyperfi-
brinolysis, it occurred repeatedly: in 3 patients during
both the preanhepatic and the anhepatic phase and in
4 patients in the anhepatic phase and after reperfu-
sion. CLIs after 60 min were 4% vs 26% (P  0.03) in
the anhepatic phase and 4% vs 40% (P  0.03) after
reperfusion (Table 2). The dose of tranexamic acid
given in both groups to patients with excessive fibri-
nolysis was similar. In the patients treated with FFP,
6500 mg of tranexamic acid was administered to six
patients (29%) (mean dose, 1083 mg per patient). In
the ESDEP-Treated group, 12 patients (60%) received
15,250 mg of tranexamic acid (mean dose, 1271 mg per
patient; not significant).
Analysis of standard coagulation variables during
the procedure revealed no significant differences be-
tween patients treated with FFP or ESDEP, except for
factor VIII after induction and the prothrombin time in
the anhepatic phase (Table 3). However, d-dimer and
FDP levels were significantly higher in the ESDEP-
treated patients in the anhepatic phase and after reper-
fusion, consistent with the increased fibrinolytic activ-
ity recorded on TEG® (Table 3).
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Also, determination of 2-antiplasmin levels showed
significant differences between treatment with FFP or
ESDEP (Fig. 1). 2-Antiplasmin levels after the onset of
anesthesia were not statistically different in the FFP- and
the ESDEP-Treated groups. In patients who received
FFP, 2-antiplasmin levels remained relatively stable
and decreased from 0.76 to 0.65 IU/mL in the anhepatic
phase, decreased to 0.58 IU/mL after reperfusion, and
leveled out at 0.58 IU/mL at the end of the procedure.
The corresponding levels in patients treated with ESDEP
were 0.64 IU/mL (not significant), 0.37 IU/mL (P 
0.001), 0.27 IU/mL (P  0.006), and 0.40 IU/mL (P 
0.03), respectively. Repeated analysis of variance con-
firmed that type of plasma was responsible for the de-
crease from baseline value, independent from the time
course. Analysis of ESDEP itself revealed normal levels
of all clotting factors (0.81 IU/mL), AT-III (0.81 IU/
mL), protein C (0.80 IU/mL), and plasminogen (0.94
IU/mL). Levels of factor VIII (0.71 IU/mL) and protein S
(0.58 IU/mL) were slightly decreased, but levels of 2-
antiplasmin were severely decreased to 0.28  0.02
IU/mL (normal, 0.95–1.20 IU/mL) (5). Linear regression
showed statistically significant relationships between the
level of 2-antiplasmin and the CLI60 (P  0.01) and
CLI60 (P  0.01), the level of FDP and CLI30 (P  0.03),
and the d-dimer level and CLI60 (P  0.01) and CLI60 (P
 0.01). Despite the increased fibrinolysis, there was no
difference in total blood loss between patients receiving
FFP or ESDEP, but blood loss was significantly larger in
the 21 of 41 patients from both groups in whom hyper-
fibrinolysis occurred (18,054  2,469 mL vs 8,683 
1,339 mL; P  0.001). In addition, the transfusion re-
quirements for PRBC, platelets, fibrinogen, and plasma
were also larger in patients with hyperfibrinolysis (all P
 0.001).
Discussion
OLT has become the standard treatment for end-stage
liver disease, but the procedure still can be associated
with severe disorders of hemostasis (9). A key role in
the pathogenesis of intraoperative bleeding is played
by enhanced fibrinolysis during the anhepatic and
reperfusion phase (10,11). To minimize the risk of viral
transmission, SD virus-inactivated plasma was intro-
duced in 1996 in our hospital, and thereafter an in-
crease in hyperfibrinolysis in patients undergoing
OLT was observed. SD treatment of FFP is an effective
method to reduce lipid-coated viruses by 5 log 10
(12,13), but it has been reported that because of the SD
process, the concentration of factor VIII, protein S, and
2-antiplasmin is reduced (5,6).
2-Antiplasmin is a main physiological inhibitor of
t-PA-induced fibrinolysis and fibrinogenolysis (14,15),
which are held responsible for uncontrollable intraop-
erative bleeding. Inhibition of this fibrinolysis may
occur at the level of plasminogen activation by plas-
minogen activator inhibitor or at the level of plasmin
by 2-antiplasmin (16). Once large amounts of t-PA
are released into the circulation of the recipient, 2-
antiplasmin plays a key role in the scavenging of the
formed free plasmin. Free plasmin is extremely rap-
idly inactivated by 2-antiplasmin; the half-life of free
plasmin is estimated to be approximately 0.1 seconds.
Without adequate 2-antiplasmin levels, a small
amount of t-PA can start the offset of systemic fibri-
nolysis (17), because the fibrin degradation products
can amplify the plasminogen activation (18).
Although the efficacy of SD plasma in clinical stud-
ies in patients with coagulation disorders has been
established (19,20), the balance between pro- and an-
tifibrinolytic activity in our patients seems to be dis-
turbed during OLT by SD plasma substitution. In
patients with chronic liver disease, enhanced fibrino-
lysis occurred approximately three times more in the
anhepatic phase and after reperfusion in patients who
received ESDEP than in patients treated with FFP.
Determination of 2-antiplasmin concentrations in
ESDEP showed decreased levels, in accordance with
the results presented in the literature (5,6). In 47% of
the patients treated with ESDEP, hyperfibrinolytic ep-
isodes did recur, despite adequate treatment of the
first hyperfibrinolytic episode, proven by normaliza-
tion of the TEG® recordings. We think that this effect
is caused by the large plasma exchanges in OLT,
which dilute the level of 2-antiplasmin in the patient
to the level of ESDEP itself.
Table 1. Basic Characteristics of Patients Undergoing
Orthotopic Liver Transplantation
Variable
FFP
(n  21)
ESDEP
(n  20)
Age (yr) 53 (23–65)* 44 (23–62)
Male/female 9/12 15/5
Indication (n)
Viral hepatitis
cirrhosis
6 6
Cholestatic liver
disease
10 8
Other cirrhosis 5 6
Operation time (min) 419 (14) 436 (21)
Blood loss (mL) 12,173 (1,907) 15,191 (3,155)
Transfusions
PRBC (U) 13.1 (1.8) 15.3 (2.9)
Cell salvage blood
(mL)
2,481 (655) 2,655 (981)
Plasma (mL) 4,271 (616) 5,440 (903)
Fibrinogen (g) 4.7 (0.8) 7.2 (1.6)
Platelets (U) 19.5 (2.4) 20.0 (3.6)
Plasma/PRBC (mL) 342 (30) 383 (26)
Values are mean (sem) or (range).
FFP  fresh frozen plasma; ESDEP®  solvent/detergent-treated plasma;
PRBC  packed red blood cells.
* P  0.05 versus ESDEP®.
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In a randomized multicenter study by Freeman et
al. (21), no differences were seen in coagulation vari-
ables between patients receiving FFP- or SD-treated
plasma during OLT, but 2-antiplasmin levels were
not determined in their study. Hyperfibrinolytic prob-
lems were not mentioned in the article, probably be-
cause of standard prophylactic use of antifibrinolytic
drugs in the participating centers in the United King-
dom. In our patients with chronic liver disease, 2-
antiplasmin levels were relatively high (0.70 IU/mL)
after the induction of anesthesia, in contrast to the
markedly reduced 2-antiplasmin levels reported for
patients with advanced liver disease (22,23). Low lev-
els of 2-antiplasmin in the anhepatic phase and after
reperfusion in the ESDEP-treated patients compared
with the FFP-treated patients explains the increase in
hyperfibrinolysis seen in the former group. At the end
of the procedure, 2-antiplasmin levels were increas-
ing in the patients treated with ESDEP, probably be-
cause of increased clearance of t-PA by the donor liver
and starting synthesis of 2-antiplasmin. In accor-
dance with the study of Freeman et al. (21), no differ-
ences were found in other coagulation variables, use
of blood products, or blood loss between the FFP- and
ESDEP-treated patients. However, patients from both
groups with hyperfibrinolysis had significantly more
Figure 1. Intraoperative time course of the 2-antiplasmin levels.
Patients with chronic liver disease treated with fresh frozen
plasma (n  21). Œ Patients with chronic liver disease treated with
solvent/detergent virus-inactivated plasma (n  20). *P  0.05; **P
 0.01.
Table 2. Coagulation Analysis Variables During Orthotopic Liver Transplantation in Patients Treated with FFP and
ESDEP
Variable
After induction Anhepatic phase After reperfusion
FFP ESDEP FFP ESDEP FFP ESDEP
R (mm) 21.7 (0.6) 23.6 (2.7) 15.5 (1.6) 16.1 (2.5) 24.1 (1.0) 29.6 (3.9)
R  K (mm) 31.0 (0.9) 32.0 (3.0) 24.6 (2.1) 23.3 (3.3) 37.5 (1.8) 44.3 (5.0)
Ang (deg) 50.1 (4.7) 42.2 (3.1) 43.7 (4.1) 52.4 (3.6) 41.5 (4.2) 33.7 (3.5)
MA (mm) 47.7 (2.5) 54.5 (3.1) 40.8 (3.0) 48.0 (3.7) 32.2 (3.2) 35.0 (3.9)
CLI30 (%) 1.6 (0.4) 3.1 (2.1) 1.7 (0.5)* 16.8 (7.5) 2.0 (0.5)* 31.6 (9.9)
CLI60 (%) 4.3 (0.8) 7.2 (2.2) 3.9 (1.1)* 26.2 (9.6) 4.2 (1.0)* 39.7 (10.7)
Values are mean (sem).
FFP fresh frozen plasma; ESDEP® solvent/detergent-treated plasma; R R time; K K time; Ang angle; MAmaximum amplitude; CLI clot lysis
index at 30 and 60 min.
* P  0.05 versus ESDEP.
Table 3. Coagulation Variables During Orthotopic Liver Transplantation
Variable
After induction Anhepatic phase After reperfusion
FFP ESDEP FFP ESDEP FFP ESDEP
aPTT (s) 43 (3) 46 (3) 68 (13) 113 (19) 157 (18) 181 (19)
PT (s) 17.6 (1.7) 15.8 (0.9) 15.1 (0.5)* 24.0 (5.5) 17.4 (1.0) 24.0 (5.2)
Thrombin time 10E (s) 17 (1) 20 (2) 19 (2) 25 (4) 26 (4) 33 (6)
Platelets ( 109/L) 108 (16) 113 (17) 89 (19) 75 (10) 90 (14) 79 (9)
Fibrinogen (g/L) 1.8 (0.1) 2.2 (0.3) 1.5 (0.1) 1.6 (0.2) 1.5 (0.1) 1.4 (0.2)
FII (IU/mL) 0.48 (0.05) 0.48 (0.05) 0.47 (0.03) 0.40 (0.04) 0.39 (0.02) 0.37 (0.03)
FVII (IU/mL) 0.43 (0.05) 0.45 (0.05) 0.41 (0.03) 0.37 (0.04) 0.34 (0.02) 0.35 (0.03)
FX (IU/mL) 0.56 (0.04) 0.55 (0.04) 0.49 (0.02) 0.44 (0.04) 0.39 (0.02) 0.38 (0.03)
FVIII (IU/mL) 2.17 (0.25)* 3.41 (0.52) 1.29 (0.21) 1.70 (0.30) 0.80 (0.12) 1.01 (0.24)
FIX (IU/mL) 0.51 (0.07) 0.58 (0.08) 0.36 (0.05) 0.36 (0.06) 0.22 (0.03) 0.19 (0.04)
D-dimer (g/mL) 0.46 (0.14) 1.01 (0.40) 1.53 (0.37)* 6.58 (1.98) 4.70 (1.97)† 23.47 (6.56)
FDP (mg/L) — — 23 (5)† 60 (16) 57 (11)† 161 (24)
Values are mean (sem).
FFP  fresh frozen plasma; ESDEP®  solvent/detergent-treated plasma; aPTT  activated partial thromboplastin time; PT  prothrombin time; FII, FVII,
FX, FVII, FIX  clotting factors.
* P  0.05 versus ESDEP; † P  0.01 versus ESDEP.
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bleeding and transfusion requirements than patients
without hyperfibrinolysis.
In summary, the results of this observational study
have to be interpreted carefully, because other factors
could have caused our findings. However, in the time
interval of this study, no changes occurred in our
operating or anesthesiology techniques, medical staff,
or transfusion protocol. Also, the increased incidence
of hyperfibrinolysis was present immediately after
switching from FFP to ESDEP. Infusion of SD-treated
plasma in patients needing massive transfusion may
lead to insufficient levels of 2-antiplasmin and sub-
sequently to secondary hyperfibrinolysis. This hyper-
fibrinolysis cannot be corrected with infusion of more
SD-treated plasma, because this would dilute the 2-
antiplasmin concentration in the patient to that of
ESDEP itself (0.28 IU/L). Therefore, it should be
treated with antifibrinolytic medication. The effects of
aprotinin on antiplasmin activity, hyperfibrinolysis,
and subsequent blood loss have been reported with
various outcomes (3,24–27). Considering the signifi-
cantly larger blood loss in patients with hyperfibrin-
olysis in our study, routine administration of antifi-
brinolytic drugs when using SD virus-inactivated
plasma is suggested.
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